|
The Bangalore District Chemists & Druggists Association (BDCDA) has urged the Karnataka government to form a high-level enforcement task force led by senior IPS officers and enforcement officials from the Karnataka Food Safety and Drug Administration (FDA) to conduct state wide operations against counterfeit drug networks.
We would be privileged to be part of this collaborative effort and remain available for consultations, field-level coordination, and voluntary compliance programmes, B. Thirunavukkarasu, president, BDCDA stated in his communication to the Karnataka chief minister and other related departments.
The need of the hour is to strengthen regulatory framework, implement stricter regulations and penalties for entities manufacturing, distributing and selling counterfeit medicines, he added.
The state FDA needs to enhance its surveillance. Investing in advanced technologies and training drug inspectors improves detection and tracking of counterfeit drugs. Launching state-wide awareness programs to educate consumers, retailers, wholesalers and healthcare professionals about the dangers of counterfeit medicines and the importance of purchasing drugs from authorized sources will help to nip this, he said.
All e-commerce platforms involved in the illegal online sale of medicines should be temporarily suspended from such operations until a robust and enforceable regulatory mechanism is established. The fight against counterfeit medicines is a battle for the health and safety people in Karnataka, he noted.
As an association of licensed chemists and druggists, BDCDA reaffirms its commitment to support the government in this mission. We request the government to look into this with utmost urgency and convene a multi-stakeholder meeting to initiate the enforcement by outlining stringent regulatory measures, stated Thirunavukkarasu in his note adding that counterfeit medicines sale is a form of ‘National Public Health Terrorism’ tarnishing India's global reputation in pharma trade.
Recent reports indicate a 50% surge in counterfeit medicines post-Covid-19, attributed to consumer preference for discounted drugs, inadequate government vigilance, and lenient prohibitive laws. While the recall of NSQ drugs is only a fraction of the problem, the root issue is the unchecked manufacturing and distribution of counterfeit medicines. Notably, Karnataka has flagged 26 medicines as misbranded or spurious, consumed for common ailments like acidity, pain relief, and cholesterol. However, absence of widespread seizures should not be misconstrued as non-existence of counterfeit drugs; rather, it underscores gaps in detection, regulatory oversight, and enforcement mechanisms, he said.
Karnataka government has acknowledged shortage of drug inspectors with only 8 out of 112 sanctioned posts filled, hampering effective surveillance and enforcement against counterfeit medicines. We propose forming a high-level task force led by IPS officers, with enforcement officers from the Karnataka FDA to embark on state-wide search and seizure operations, ensuring stringent punishment of culprits in counterfeit drug trade, said the BDCDA chief.
The integrity of QR codes, introduced as an anti-counterfeiting measure, is compromised. Reports indicate that counterfeiters have successfully replicated functional QR codes on fake medicine packages, rendering the current authentication system ineffective. This breach undermines trust in pharmaceutical products. We observe unauthorized supplies infiltrate into Karnataka through semi-wholesalers, procuring agents, and sub-stockists, supplying counterfeit medicines to unregulated e-commerce platforms, exacerbating the spread of fake drugs, said Thirunavukkarasu.
India’s online medicine sale continues to operate in an unregulated environment. Numerous e-commerce platforms and quick commerce services actively sell and deliver medicines directly to consumers in the absence of a universally applicable legal framework and consistent regulatory oversight. It impacts patient safety, drug authenticity, and the unchecked misuse of prescription medications. Absence of professional pharmaceutical guidance and accountability on these platforms compounds the risk, making this an urgent issue of national concern, said Thirunavukkarasu.
|